Established in 1989, Jafron Biomedical (ChiNext: JFSW) is a global provider of technology, product and therapy service in the hemoadsorption industry. With a market value of $7 billion, Jafron has three branches, 11 subsidiaries, one sub-subsidiary and medical foundation, insurance, etc. Jafron has diligently devoted to the R&D, production and sales of blood purification products primarily in the hemoadsorption field for decades. It is dedicated to providing professional services to patients worldwide, covering ESRD diseases, acute poisoning, critical illness, hepatopathy, immunological disorders, etc.
The company set 183 offices in China and five global service centers, including Vietnam, Europe, South America, etc., with a professional therapy-providing team of over 1,100 staff and 1,000 partners. With more than 20-years of clinical experience, the company's flagship product, "HA series disposable hemoperfusion cartridge," originally developed by Jafron, has been adopted in more than 8,000 key hospitals across 80 countries and regions, with 5 million cases of clinical application annually.
As a global adsorption therapies provider, Jafron is involved in all aspects of exploring solutions for disease, from research and development of new hemoperfusion therapies to manufacturing our hemoadsorption products, right through to offering comprehensive therapy options. Jafron will not rest in its effort to explore novel medical fields to save lives, improve patients' quality of life, and realize the vision of "Health Technology for a better world." See more details on www.jafron.com.